Systematic review of chimpanzee use in monoclonal antibody research and drug development: 1981-2010

Altex

Volumn 28, Issue 2, 2011, Pages 103-116

  Bettauer, Raija H ^a  

^a Bettauer BioMed Research   (United States)

Author keywords

Animal model; Chimpanzee; Monoclonal antibodies; Preclinical studies

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CANAKINUMAB; CAPROMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; DENOSUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; IBRITUMOMAB TIUXETAN; IMCIROMAB PENTETATE; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; PROSTACINT; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; USTEKINUMAB;

ANALGESIA; ANESTHESIA; BIOPSY TECHNIQUE; BLOOD SAMPLING; BODY FLUID; CHIMPANZEE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; IMMUNIZATION; NONHUMAN; REVIEW; SYSTEMATIC REVIEW (TOPIC); ANIMAL; ANIMAL TESTING ALTERNATIVE; ANIMAL WELFARE; METHODOLOGY; PAN TROGLODYTES;

ANIMAL TESTING ALTERNATIVES; ANIMAL WELFARE; ANIMALS; ANTIBODIES, MONOCLONAL; PAN TROGLODYTES; RESEARCH DESIGN;

EID: 80052913195     PISSN: 09467785     EISSN: None     Source Type: Journal    
DOI: 10.14573/altex.2011.2.103     Document Type: Review

References (100)

1. Abi-Rached, L., Moesta, A. K., Rajalingam, R. et al. (2010). Human-specific evolution and adaptation led to major qualitative differences in the variable receptors of human and chimpanzee natural killer cells. PLoS Genet. 6, e1001192.
2. Alley, S. C., Benjamin, D. C. and Law, C.-L. (2009). Antibodydrug conjugate therapy. In Z. An (ed.), Therapeutic monoclonal antibodies (821-855). Hoboken, NJ, USA: John Wiley & Sons, Inc.
3. Almagro, J. C. and Strohl, W. R. (2009). Antibody engineering: Humanization, affinity maturation, and selection techniques. In Z. An (ed.), Therapeutic monoclonal antibodies (311-334). Hoboken, NJ, USA: John Wiley & Sons, Inc.
4. Apoil, P. A., Reid, M. E., Halverson, G. et al. (1997). A human monoclonal anti-D antibody which detects a nonconformation-dependent epitope on the RHD protein by immunoblot. Br. J. Haematol. 98, 365-374.
5. Arp, J., LeVatte, M., Rowe, J. et al. (1996). A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: Expression of gp46 by the vaccinia virus/T7 polymerase system. J. Virol. 70, 7349-7359. (Pubitemid 26339039)
6. Bauer, R. J., Dedrick, R. L., White, M. L. et al. (1999). Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J. Pharmacokinet. Biopharm. 27, 397-420. (Pubitemid 30228022)
7. Bhogal, N., Combes, R. and Balls, M. (2008). Preclinical drug development planning. In S. C. Gad (ed.), Preclinical drug development handbook: Toxicology (1-64). Hoboken, NJ, USA: John Wiley & Sons, Inc.
8. Blancher A. and Socha W. W. (1991). Anti-human red cell monoclonal antibodies produced by macaque-mouse heterohybridomas. J. Med. Primatol. 20, 352-356.
9. Blancher, A., Socha, W. W. and Ruffie, J. (1992). Diversity of human anti-D monoclonal antibodies revealed by reactions with chimpanzee red blood cells. Vox Sang 63, 112-118.
10. Blewett, E. L., Saliki, J. T. and Eberle, R. (1999). Development of a competitive ELISA for detection of primates infected with monkey B virus (Herpesvirus simiae). J. Virol. Methods 77, 59-67. (Pubitemid 29027981)
11. Boon, L., Holland, B., Gordon, W. et al. (2002). Development of anti-CD4 mAb hu5a8 for treatment of HIV-1 infection: Preclinical assessment in non-human primates. Toxicology 172, 191-203. (Pubitemid 34219385)
12. ++ adenosine triphosphatase pump recognize an epitope in the basolateral membrane of human kidney distal tubule cells. J. Clin. Invest. 80, 1225-1231.
13. Brekke, O. H. and Sandlie, I. (2003). Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2, 52-62. (Pubitemid 37361624)
14. Bukh, J., Thimme, R., Meunier, J.-C. et al. (2008). Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J. Virol. 82, 8183-8195.
15. Chen, Z., Earl, P., Americo, J. et al. (2006a). Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. USA 103, 1882-1887. (Pubitemid 43228787)
16. Chen, Z., Moayeri, M., Zhou, Y. H. et al. (2006b). Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis. 193, 625-633. (Pubitemid 43271496)
17. Chimpanzee Sequencing and Analysis Consortium (2005). Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 437, 69-87.
18. Crowe, J., Jr., Cheung, P., Wallace, E. et al. (1994). Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus. Clin. Diagn. Lab. Immunol. 1, 701-706. (Pubitemid 2164303)
19. Dowell, B. L., Tuck, F. L., Borowitz, M. J. et al. (1984). Phylogenetic distribution of a 24,000 dalton human leukemia-associated antigen on platelets and kidney cells. Dev. Comp. Immunol. 8, 187-195. (Pubitemid 14113957)
20. Ehrlich, P. H., Moustafa, Z. A., Justice, J. C. et al. (1988). Human and primate monoclonal antibodies for in vivo therapy. Clin. Chem. 34, 1681-1688.
21. Emini, E. A., Schleif, W. A., Nunberg, J. H. et al. (1992). Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730.
22. Esumi, M., Zhou, Y. H., Tanoue, T. et al. (2002). In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus. Vaccine 20, 3095-3103.
23. FDA (1996). The Center for Drug Evaluation and Research: Application Number NDA 21174. Pharmacology review(s) Part 1. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2000/21174-MYLOTARG-pharmr-P1.pdf
24. FDA (1998). Pharmacology of the infliximab BLA. http://www.fda.gov/ downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/TherapeuticBiologicApplications/ucm107706.pdf
25. FDA (1999). Pharmacology review of the infliximab BLA. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm107724.pdf
26. FDA (2000). The Center for Drug Evaluation and Research: Application number NDA 21174. Pharmacology review(s). Part 2. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2000/21174-MYLOTARG-pharmr-P2.pdf
27. FDA (2003). Efalizumab (Raptiva) approval letter. http://www.fda.gov/ downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/TherapeuticBiologicApplications/ucm080736.pdf
28. FDA (2007). Center for Drug Evaluation and Review. Application number 125166: Pharmacology review. http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2007/125166s0000-PharmR.pdf
29. FDA (2009a). The Center for Drug Evaluation and Research: Application number 125261. Pharmacology review(s). http://www.accessdata.fda.gov/drugsatfda- docs/nda/2009/125261s000-PharmR.pdf
30. FDA (2009b). FDA Alert: Information on Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm109340.htm
31. FDA (2009c). Raptiva (efalizumab) Feb 2009 - Safety information. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm149675.htm
32. FDA (2010a). CDER Therapeutic Biologic Products. http://www.fda.gov/ downloads/ForIndustry/UserrFees/PrescriptionDrugUseerFee/UCM164641.pdf
33. FDA (2010b). Label and approval history of Orthoclone OKT3. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Label-ApprovalHistory#apphist
34. FDA (2010c). Mylotarg (gemtuzumab ozogamicin): Market Withdrawal. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm216458.htm
35. Fishwild, D. M., Hudson, D. V., Deshpande, U. et al. (1999). Differential effects of administration of a human anti-CD4 monoclonal antibody, hm6g, in nonhuman primates. Clin. Immunol. 92, 138-152. (Pubitemid 29362544)
36. Forns, X., Payette, P. J., Ma, X. et al. (2000). Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32, 618-625.
37. Franzoso, G., Hu, P. C., Meloni, G. A. and Barile, M. F. (1993). The immunodominant 90-kilodalton protein is localized on the terminal tip structure of Mycoplasma pneumoniae. Infect. Immun. 61, 1523-1530. (Pubitemid 23099231)
38. Fridman, E. (2002). Medical primatology. R. D. Nadler (ed.). New York: Francis & Taylor.
39. Geijtenbeek, T. B., Koopman, G., van Duijnhoven, G. C. et al. (2001). Rhesus macaque and chimpanzee DC-SIGN act as HIV/SIV gp120 trans-receptors, similar to human DC-SIGN. Immunol. Lett. 79, 101-107. (Pubitemid 32938214)
40. Genentech (2003). Dermatologic and Ophtalmic Drugs Advisory Committee Meeting, 9 September 2003: Raptiva(TM) (Efalizumab). http://www.fda.gov/ohrms/ dockets/ac/03/briefing/3983B1-01-Genentech-Raptiva.htm
41. Gibson, C. R., Sandhu, P. and Hanley, W. D. (2009). Monoclonal antibody pharmacokinetics and pharmacodynamics. In Z. An (ed.), Therapeutic monoclonal antibodies (439-460). Hoboken, NJ, USA: John Wiley & Sons, Inc.
42. Goncalvez, A. P., Chien, C.-H., Tubthong, K. et al. (2008). Humanized monoclonal antibodies derived from chimpanzee fabs protect against Japanese encephalitis virus in vitro and in vivo. J. Virol. 82, 7009-7021. (Pubitemid 351977721)
43. Goudsmit, J., Smit, L., Klaver, B. et al. (1987). Induction in chimpanzees of antibodies inhibiting receptor-mediated cell fusion by HIV glycoprotein. Viral Immunol. 1, 225-240.
44. Hammond, G. L. and Robinson, P. A. (1984). Characterization of a monoclonal antibody to human sex hormone binding globulin. FEBS Lett. 168, 307-312. (Pubitemid 14130861)
45. Harpprecht, J., Jonker, M., Podzuweit, H. G. et al. (1990). Human monoclonal antibody ha6d3, a candidate for treatment of leukaemia? In vitro reactivity of ha6d3 with leukaemic cells and in vivo applications in a chimpanzee. Br. J. Cancer, Suppl. 10, 44-47. (Pubitemid 20226481)
46. Hatziioannou, T., Ambrose, Z., Chung, N. P. Y. et al. (2009). A macaque model of HIV-1 infection. Proc. Natl. Acad. Sci. USA 106, 4425-4429.
47. ICH - International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (1997). Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6. ICH Harmonized Tripartite Guideline. http://www.ich.org/LOB/media/MEDIA3599.pdf
48. Iwarson, S., Tabor, E., Thomas, H. C. et al. (1985). Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J. Med. Virol. 16, 89-96. (Pubitemid 15098392)
49. Jansen, J., van der Poll, T., Levi, M. et al. (1995). Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody. J. Clin. Immunol. 15, 45-50.
50. Jonker, M., Nooij, F. J., Den Butter, G. et al. (1988). Side effects and immunogenicity of murine lymphocyte-specific monoclonal antibodies in subhuman primates. Transplantation 45, 677-682.
51. Jonker, M., Slingerland, W., Treacy, G. et al. (1993). In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees. Clin. Exp. Immunol. 93, 301-307. (Pubitemid 23276251)
52. Kim, S.-H., Shin, Y. W., Hong, K.-W. et al. (2008). Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees. Antiviral Research 79, 188-191.
53. Klotz, F. W., Cohen, S. J., Szarfman, A. et al. (1996). Cross-reactive epitope among proteins in Plasmodium falciparum Maurer's clefts and primate leukocytes and platelets. Am. J. Trop. Med. Hyg. 54, 655-659. (Pubitemid 26238840)
54. Levi, M., ten Cate, H., Bauer, K. A. et al. (1994). Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J. Clin. Invest. 93, 114-120. (Pubitemid 24030827)
55. Levi, M., van Der, P. T., ten Cate, H. et al. (1998). Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. Am. J. Respir. Crit. Care Med. 158, 92-98.
56. Logdberg, L., Kaplan, E., Drelich, M. et al. (1994). Primate antibodies to components of the human immune system. J. Med. Primatol. 23, 285-297.
57. Loisel, S., Ohresser, M., Pallardy, M. et al. (2007). Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit. Rev. Oncol. Hematol. 62, 34-42. (Pubitemid 46330797)
58. Lu, Y. Q., Liu, J. F., Socha, W. et al. (1987). Polymorphism of glycophorins in nonhuman primate erythrocytes. Biochem. Genet. 25, 477-491.
59. Maillard, P., Krawczynski, K., Nitkiewicz, J. et al. (2001). Non-enveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J. Virol. 75, 8240-8250. (Pubitemid 32743696)
60. McCauley, T. C., Kurth, B. E., Norton, E. J. et al. (2002). Analysis of a human sperm CD52 glycoform in primates: Identification of an animal model for immunocontraceptive vaccine development. Biol. Reprod. 66, 1681-1688. (Pubitemid 34547262)
61. Men, R., Yamashiro, T., Goncalvez, A. P. et al. (2004). Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of Dengue type 4 virus. J Virol. 78, 4665-4674. (Pubitemid 38501088)
62. Meunier, J. C., Russell, R. S., Goossens, V. et al. (2008). Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J. Virol. 82, 966-973.
63. Moller, A., Emling, F., Blohm, D. et al. (1990). Monoclonal antibodies to human tumor necrosis factor alpha: In vitro and in vivo application. Cytokine 2, 162-169.
64. Nardin, E. H., Nussenzweig, V., Nussenzweig, R. S. et al. (1982). Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 156, 20-30. (Pubitemid 12082484)
65. National Science Board (2002). Public Attitudes Toward Science&Technology, Scientific Research, Federal Funding of Scientific Research, and Specific Science-Related Issues. http://www.nsf.gov/statistics/ seind02/c7/c7s2.htm#c7s214
66. Neubauer, R. H., Levy, R., Strand, B. C. and Rabin, H. (1981). Reactivity of monoclonal antibodies against human leucocyte antigens with lymphocytes of non-human primate origin. J. Immunogenet. 8, 433-442. (Pubitemid 12159417)
67. Newman, R., Hariharan, K., Reff, M. et al. (2001). Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees. Clin. Immunol. 98, 164-174.
68. Nguyen, D. H. (2006). Loss of siglec expression on T lymphocytes during human evolution. Proc. Natl. Acad. Sci. USA 103, 7765-7770.
69. Ogata, N., Ostberg, L., Ehrlich, P. H. et al. (1993). Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc. Natl. Acad. Sci. USA 90, 3014-3018. (Pubitemid 23113548)
70. Palmer, D. K., Morse, H. G. and Jones, C. (1987). Three distinct epitopes of the human MSK20 cell surface antigen are expressed on human and nonhuman primate cells. Mol. Immunol. 24, 865-869. (Pubitemid 17095912)
71. Parleviet, K. J., Jonker, M., ten Berge, R. J. et al. (1990). Anti-CD3 murine monoclonal isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzees. Transplantation 50, 889-892.
72. Perry, G. H., Yang, F., Marques-Bonet, T. et al. (2008). Copy number variation and evolution in humans and chimpanzees. Genome Research 18, 1698-1710.
73. Rao, P. E., Olini, G., Kille, J. et al. (1991). OKT3E, an anti-CD3 antibody that does not elicit side effects or antiidiotype responses in chimpanzees. Transplantation 52, 691-697.
74. Sawada, H., Iwasa, S., Nishimura, O. and Kitano, K. (1995). Efficient production of anti-(hepatitis B virus) antibodies and their neutralizing activity in chimpanzees. Appl. Microbiol. Biotechnol. 43, 445-451.
75. Schofield, D. J., Glamann, J., Emerson, S. U. and Purcell, R. H. (2000). Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J. Virol. 74, 5548-5555. (Pubitemid 30346588)
76. Schofield, D. J., Satterfield, W., Emerson, S. U. and Purcell, R. H. (2002). Four chimpanzee monoclonal antibodies isolated by phage display neutralize hepatitis A virus. Virology 292, 127-136.
77. Shaw, M. A. (1986). Monoclonal anti-LWab and anti-D reagents recognize a number of different epitopes. Use of red cells of non-human primates. J. Immunogenet. 13, 377-86.
78. Socha, W. W., Blancher, A. and Ruffie, J. (1993). Comparative study of human monoclonal anti-D antibodies of IgG and IgM classes in tests with red cells of nonhuman primates. Rev. Fr. Transfus. Hemobiol. 36, 485-497.
79. Socha, W. W. and Moor-Jankowski, J. (1993). The M-N - V-AB-D blood group system of chimpanzee and other apes: serology and genetics. J. Med. Primatol. 22, 3-6.
80. Socha, W. W. and Ruffie, J. (1990). Monoclonal antibodies directed against human Rh antigens in tests with the red cells of nonhuman primates. Rev. Fr. Transfus. Hemobiol. 33, 39-48.
81. Soto, P. C., Stein, L. L., Hurtado-Ziola, N. et al. (2010). Relative over-reactivity of human versus chimpanzee lymphocytes: Implications for the human diseases associated with immune activation. J. Immunol. 185, 4233-4237.
82. Strohl, W. R. (2009). Therapeutic monoclonal antibodies: Past, present, and future. In Z. An (ed.), Therapeutic monoclonal antibodies (3-50). Hoboken, NJ, USA: John Wiley & Sons, Inc.
83. Takahashi, K., Mishiro, S. and Prince, A. M. (2001). Novel hepatitis B virus strain from a chimpanzee of Central Africa (Pan troglodytes troglodytes) with an unusual antigenicity of the core protein. Intervirology 44, 321-326. (Pubitemid 34701948)
84. ten Cate, H., Bauer, K. A., Levi, M. et al. (1993). The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J. Clin. Invest. 92, 1207-1212. (Pubitemid 23273893)
85. The Pew Research Center for the People & the Press and The American Association for the Advancement of Science (2009). Public praises science; Scientists fault public, media. http://people-press.org/report/?pageid=1550
86. Thirkell, D., Myles, A. D. and Taylor-Robinson, D. (1990). A comparison of four major antigens in five human and several animal strains of ureaplasmas. J. Med. Microbiol. 32, 163-168. (Pubitemid 20217353)
87. Toh, B. H., Gibbs, C. J., Jr., Gajdusek, D. C. et al. (1985). The 200- and 150-kDa neurofilament proteins react with IgG autoantibodies from chimpanzees with kuru or Creutzfeldt-Jakob disease; a 62-kDa neurofilament-associated protein reacts with sera from sheep with natural scrapie. Proc. Natl. Acad. Sci. USA 82, 3894-3896. (Pubitemid 15246459)
88. Tournamille, C., Blancher, A., Le Van Kim, C. et al. (2004). Sequence, evolution and ligand binding properties of mammalian Duffy antigen/receptor for chemokines. Immunogenetics 55, 682-694. (Pubitemid 38221668)
89. van der Poll, T., Jansen, J., Levi, M. et al. (1996). Interleukin 10 release during endotoxaemia in chimpanzees: Role of platelet-activating factor and interleukin 6. Scand. J. Immunol. 43, 122-125. (Pubitemid 26024536)
90. van Meurs, G. J. and Jonker, M. (1986). Production of primate monoclonal antibodies. J. Immunol. Methods 95, 123-128.
91. VandeBerg, J. L., Zola, S. M., Ely, J. J. and Kennedy, R. C. (2006). Monoclonal antibody testing. J. Med. Primatol. 35, 405-406.
92. Wang, C. Y., Sawyer, L. S., Murthy, K. K. et al. (1999). Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc. Natl. Acad. Sci. USA 96, 10367-10372. (Pubitemid 29422564)
93. Wang, W., Wang, E. Q. and Balthasar, J. P. (2008). Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84, 548-558.
94. Weinstock, G. M. (2007). ENCODE: More genomic empowerment. Genome Research 17, 667-668.
95. Winton, E. F., Colenda, K. W., McClure, H. M. et al. (1985). Studies on the use of nonhuman primates to determine the DR status of the human hematopoietic stem cell. Exp. Hematol. 13, 869-73. (Pubitemid 16234191)
96. Wong, H., Grossman, S. J., Bai, S. A. et al. (2004). The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: Model characterization and application. Drug Metab. Dispos. 32, 1359-1369. (Pubitemid 39564555)
97. Wood, B. (2006). The evolutionary relationships of humans and apes: What we know about human phenotypic specializations. In Arthur M. Sackler (ed.), Colloquia of the National Academy of Sciences: The New Comparative Biology of Human Nature. http://www.nasonline.org/site/PageServer?pagename=SACKLER- neurosciences-program
98. World Health Organization (2009). International nonproprietary names. The World Health Organization Drug Information 23:3. http://www.who.int/medicines/ publications/druginformation/issues/DrugInfo09vol23-3/en/
99. Zhang, P., Yu, M. Y., Venable, R. et al. (2006). Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees. Proc. Natl. Acad. Sci. USA 103, 9214-9219. (Pubitemid 43902558)
100. Zhou, Y. H., Moriyama, M. and Esumi, M. (1999). Multiple sequence-reactive antibodies induced by a single peptide immunization with hypervariable region 1 of hepatitis C virus. Virology 256, 360-370. (Pubitemid 29393371)